In the shadow of a mounting antimicrobial resistance (AMR) crisis, India stands at a critical crossroads. With drug-resistant infections claiming nearly 300,000 lives in 2019 alone, according to ICMR data, and resistance rates soaring to 80% for pathogens like carbapenem-resistant Acinetobacter baumannii, traditional antibiotics are losing ground fast. Overuse, inadequate diagnostics, and environmental factors have fueled this epidemic, demanding bold, next-generation defenses. As Saransh Chaudhary, President of Global Critical Care at Venus Remedies Ltd and CEO of Venus Medicine Research Centre, notes: Enter anti-virulence therapies and phage therapy precision tools that disarm pathogens and target them selectively, preserving our existing drugs while charting a path to sustainable infection control.
Antimicrobial resistance continues to accelerate at a pace that is now impossible to ignore. Overuse and misuse of antibiotics, a heavy infectious-disease burden, inadequate diagnostic guidance, and environmental contamination from pharmaceutical waste all contribute to a crisis that is outpacing current global response strategies. The challenge now is to expand the defensive toolkit against resistant infections rather than relying on surface-level fixes. Most importantly, the work cannot wait. The window for slow action has closed.
The scale of the problem is stark. A recent WHO analysis reported that nearly one in six laboratory-confirmed bacterial infections worldwide is now resistant to first-line antibiotics. India faces an even more acute situation. ICMR estimates that drug-resistant infections caused roughly 297,000 deaths in 2019, and resistance levels for high-priority pathogens such as Acinetobacter baumannii are close to eighty percent for carbapenems. The gap between life-saving therapy and ineffective treatment is narrowing at an alarming rate.
New scientific strategies built around pathogen disarmament
One emerging approach involves anti-virulence therapies. These do not attempt to kill bacteria directly. Instead, they neutralize the molecular tools that enable bacteria to cause disease. By blocking toxins, adhesion factors, biofilm formation, or quorum-sensing signals, these agents weaken the pathogen without applying the intense selective pressure that drives resistance to conventional antibiotics. The idea is simple but powerful: make the infection far easier to treat with existing drugs or, in some cases, enable host immunity to gain the upper hand.
Early work in this area is encouraging. The VFDB 2025 database documents the vast landscape of virulence factors across pathogens, and scientific reviews of quorum-sensing inhibitors and toxin blockers illustrate how broad the field has become. A recent Indian study has shown that linoleic acid can reduce virulence in multidrug-resistant Klebsiella pneumoniae, providing a locally relevant example of the concept in action. Most anti-virulence candidates are still in preclinical development, and they are meant to complement antibiotics, not replace them. Their role is to extend the useful life of our current drugs by taking away the pathogen’s advantage.
Phage therapy: precision weapons in a crowded field
Bacteriophages offer a different kind of promise. These viruses infect and kill bacteria with remarkable specificity while leaving human cells untouched. Phage therapy has shown success in difficult cases, including a well-documented report of inhaled phages clearing a carbapenem-resistant Pseudomonas aeruginosa lung infection after conventional therapies had failed.
Regulatory momentum is now building. The United States FDA has granted investigational new drug status to personalized phage banks under Adaptive Phage Therapeutics. Georgia and Russia already allow the sale of ready-made phage cocktails, and both countries have frameworks for customized formulations prepared for individual patients. These approaches differ in implementation but share an important principle: phage therapy is treated as a legitimate pharmaceutical modality.
India is beginning to move in this direction as well. ICMR has convened scientific working groups to evaluate regulatory pathways for phages and to explore the establishment of specialized centers. More detailed guidance is expected as the country considers how to integrate phage therapy into its AMR response.
A combined future: weakening pathogens and striking them precisely
The most interesting opportunities lie at the intersection of these innovations. Anti-virulence agents may increase bacterial susceptibility to phages and antibiotics. Phages can clear bacterial populations that would otherwise persist after antibiotic exposure. Evidence suggests that personalised phage therapy, when combined with an appropriate antibiotic, achieves better clinical outcomes than either approach alone. Used together, these tools can reduce antibiotic load, slow the emergence of resistance, and lower relapse rates.
Turning promise into practice
For these strategies to reach patients, they must meet the same scientific and regulatory standards as any other therapeutic. Clinical validation, scalable manufacturing, standardized protocols, and clear regulatory pathways are essential. Investment in early-stage research, particularly for non-traditional antimicrobials, remains limited globally and needs to expand. Regional phage banks and shared preclinical infrastructure could dramatically accelerate access. National AMR action plans should also integrate these modalities rather than treating them as peripheral.
Antibiotics will remain the backbone of infectious-disease treatment for the foreseeable future. But they can no longer carry the entire burden alone. Protecting their power requires an approach that strengthens what we have while building what we lack. Anti-virulence agents and phage therapies offer a new generation of intelligent defenses that complement, rather than compete with, existing drugs. They point toward a future where infections are managed with greater precision and with far less collateral damage to patients and health systems.
India carries one of the highest burdens of AMR in the world. That reality should motivate deeper scientific investment, stronger policy momentum, and strategic partnerships that bridge basic research with practical deployment. The future of infection management will not be defined by abandoning antibiotics but by evolving the science around them so that they continue to work for the decades ahead.
